Moleculin Biotech regains Nasdaq compliance, avoiding delisting

Moleculin Biotech, Inc.

Nasdaq staff notified Panel on Jan 6, 2026 that Moleculin regained compliance with Listing Rule 5550(b)(1) (min $2.5M equity).
Company received delist determination on Nov 20, 2025 and had appealed; hearing now cancelled.
Company is in compliance with all applicable Nasdaq continued listing standards as of Jan 6, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.